MicroRNA-190b Targets RFWD3 in Estrogen Receptor–Positive Breast Cancer

Autor: Elisabet Alexandra Frick, Karen Kristjansdottir, Snaedís Ragnarsdottir, Arnar Ingi Vilhjalmsson, Maria Rose Bustos, Linda Vidarsdottir, Thorkell Gudjonsson, Stefan Sigurdsson

Publikováno v: Breast Cancer: Basic and Clinical Research, Vol 18 (2024)

Background: In the year 2020, breast cancer was the most common form of cancer worldwide. Roughly 70% of breast cancers are estrogen receptor–positive (ER+). MicroRNA-190b (miR-190b) has previously been reported to be upregulated in ER+ breast canc

Externí odkaz: https://doaj.org/article/e0ec1cd6b9804f6db2ef983b9896a6c5

PTENP1-AS contributes to BRAF inhibitor resistance and is associated with adverse clinical outcome in stage III melanoma

Autor: Linda Vidarsdottir, Alireza Azimi, Ishani Das, Ingibjorg Sigvaldadottir, Aldwin Suryo Rahmanto, Andreas Petri, Sakari Kauppinen, Christian Ingvar, Göran Jönsson, Håkan Olsson, Marianne Frostvik Stolt, Rainer Tuominen, Olle Sangfelt, Katja Pokrovskaja Tamm, Johan Hansson, Dan Grandér, Suzanne Egyházi Brage, Per Johnsson

Publikováno v: Scientific Reports, Vol 11, Iss 1, Pp 1-11 (2021)

Abstract BRAF inhibitors (BRAFi) selectively target oncogenic BRAFV600E/K and are effective in 80% of advanced cutaneous malignant melanoma cases carrying the V600 mutation. However, the development of drug resistance limits their clinical efficacy.

Externí odkaz: https://doaj.org/article/f88ae22862f24b9684552bdca23e8edf

Targeting Plk1 with siRNNs in primary cells from pediatric B-cell acute lymphoblastic leukemia patients

Autor: Alexander S. Hamil, Linda Vidarsdottir, Oksana Goroshchuk, Steven F. Dowdy, Ann-Charlotte Björklund, Caroline Palm-Apergi, Iryna Kolosenko

Publikováno v: Scientific Reports, Vol 10, Iss 1, Pp 1-10 (2020)
Scientific Reports

B-cell acute lymphoblastic leukemia (B-ALL) accounts for nearly one fifth of all childhood cancers and current challenges in B-ALL treatment include resistance, relapse and late-onset side effects due to the chemotherapy. To overcome these hurdles, n

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ac426e2e93072b4dc807e1cd9454963f
http://link.springer.com/article/10.1038/s41598-020-59653-5

PTENP1-AS contributes to BRAF inhibitor resistance and is associated with adverse clinical outcome in stage III melanoma

Autor: Marianne Frostvik Stolt, Rainer Tuominen, Dan Grandér, Ishani Das, Per Johnsson, Aldwin Suryo Rahmanto, Johan Hansson, Håkan Olsson, Göran Jönsson, Sakari Kauppinen, Alireza Azimi, Christian Ingvar, Linda Vidarsdottir, Ingibjorg Sigvaldadottir, Andreas Petri, Olle Sangfelt, Katja Pokrovskaja Tamm, Suzanne Egyhazi Brage

Publikováno v: Vidarsdottir, L, Azimi, A, Das, I, Sigvaldadottir, I, Suryo Rahmanto, A, Petri, A, Kauppinen, S, Ingvar, C, Jönsson, G, Olsson, H, Frostvik Stolt, M, Tuominen, R, Sangfelt, O, Pokrovskaja Tamm, K, Hansson, J, Grandér, D, Egyházi Brage, S & Johnsson, P 2021, ' PTENP1-AS contributes to BRAF inhibitor resistance and is associated with adverse clinical outcome in stage III melanoma ', Scientific Reports, vol. 11, no. 1, 11023 . https://doi.org/10.1038/s41598-021-89389-9
Scientific Reports, Vol 11, Iss 1, Pp 1-11 (2021)
Scientific Reports

BRAF inhibitors (BRAFi) selectively target oncogenic BRAFV600E/K and are effective in 80% of advanced cutaneous malignant melanoma cases carrying the V600 mutation. However, the development of drug resistance limits their clinical efficacy. Better ch

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::450435b6413ba470b4e369e6f91f03c9
https://vbn.aau.dk/da/publications/4126c388-b76b-418b-bab9-cd4b3824935b

PTENP1-AS contributes to BRAF inhibitor resistance and is associated with adverse clinical outcome in stage III melanoma

Autor: Göran Jönsson, Katja Pokrovskaja, Marianne Frostvik-Stolt, Andreas Petri, Dan Grandér, Håkan Olsson, Sakari Kauppinen, Rainer Tuominen, Linda Vidarsdottir, Alireza Azimi, Olle Sangfelt, Per Johnsson, Johan Hansson, suzanne Egyhazi-Brage, Aldwin Suryo Rahmanto, Christian Ingvar, Ingibjorg Sigvaldadottir

Approximately 50% of human cutaneous melanomas carry activating mutations in the serine/threonine protein kinase BRAF. BRAF inhibitors (BRAFi) selectively target the oncogenic BRAFV600E/K and are effective in approximately 80% of patients carrying th

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::97eb6995566fafd202c10d56ebbe344e